Cargando…

The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide

Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a granulomatous systemic disease caused by the thermo-dimorphic fungus Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayorga, Oriana, Muñoz, Julian E., Lincopan, Nilton, Teixeira, Aline F., Ferreira, Luis C. S., Travassos, Luiz R., Taborda, Carlos P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343455/
https://www.ncbi.nlm.nih.gov/pubmed/22586420
http://dx.doi.org/10.3389/fmicb.2012.00154
_version_ 1782231828208287744
author Mayorga, Oriana
Muñoz, Julian E.
Lincopan, Nilton
Teixeira, Aline F.
Ferreira, Luis C. S.
Travassos, Luiz R.
Taborda, Carlos P.
author_facet Mayorga, Oriana
Muñoz, Julian E.
Lincopan, Nilton
Teixeira, Aline F.
Ferreira, Luis C. S.
Travassos, Luiz R.
Taborda, Carlos P.
author_sort Mayorga, Oriana
collection PubMed
description Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a granulomatous systemic disease caused by the thermo-dimorphic fungus Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known as P10, defines a major CD4(+)-specific T cell epitope. Previous results have indicated that, besides having a preventive role in conventional immunizations prior to challenge with the fungus, protective anti-fungal effects can be induced in P. brasiliensis-infected mice treated with P10 administered with complete Freund’s adjuvant (CFA). The peptide elicits an IFN-γ-dependent Th1 immune response and is the main candidate for effective immunotherapy of patients with PCM, as an adjunctive approach to conventional chemotherapy. In the present study we tested the therapeutic effects of P10 combined with different adjuvants [aluminum hydroxide, CFA, flagellin, and the cationic lipid dioctadecyl-dimethylammonium bromide (DODAB)] in BALB/c mice previously infected with the P. brasiliensis Pb18 strain. Significant reductions in the number of colony forming units of the fungus were detected in lungs of mice immunized with P10 associated with the different adjuvants 52 days after infection. Mice treated with DODAB and P10, followed by mice treated with P10 and flagellin, showed the most prominent effects as demonstrated by the lowest numbers of viable yeast cells as well as reductions in granuloma formation and fibrosis. Concomitantly, secretion of IFN-γ and TNF-α, in contrast to interleukin (IL)-4 and IL-10, was enhanced in the lungs of mice immunized with P10 in combination with the tested adjuvants, with the best results observed in mice treated with P10 and DODAB. In conclusion, the present results demonstrate that the co-administration of the synthetic P10 peptide with several adjuvants, particularly DODAB, have significant therapeutic effects in experimental PCM.
format Online
Article
Text
id pubmed-3343455
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33434552012-05-14 The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide Mayorga, Oriana Muñoz, Julian E. Lincopan, Nilton Teixeira, Aline F. Ferreira, Luis C. S. Travassos, Luiz R. Taborda, Carlos P. Front Microbiol Microbiology Paracoccidioidomycosis (PCM), a common chronic mycosis in Latin America, is a granulomatous systemic disease caused by the thermo-dimorphic fungus Paracoccidioides brasiliensis. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known as P10, defines a major CD4(+)-specific T cell epitope. Previous results have indicated that, besides having a preventive role in conventional immunizations prior to challenge with the fungus, protective anti-fungal effects can be induced in P. brasiliensis-infected mice treated with P10 administered with complete Freund’s adjuvant (CFA). The peptide elicits an IFN-γ-dependent Th1 immune response and is the main candidate for effective immunotherapy of patients with PCM, as an adjunctive approach to conventional chemotherapy. In the present study we tested the therapeutic effects of P10 combined with different adjuvants [aluminum hydroxide, CFA, flagellin, and the cationic lipid dioctadecyl-dimethylammonium bromide (DODAB)] in BALB/c mice previously infected with the P. brasiliensis Pb18 strain. Significant reductions in the number of colony forming units of the fungus were detected in lungs of mice immunized with P10 associated with the different adjuvants 52 days after infection. Mice treated with DODAB and P10, followed by mice treated with P10 and flagellin, showed the most prominent effects as demonstrated by the lowest numbers of viable yeast cells as well as reductions in granuloma formation and fibrosis. Concomitantly, secretion of IFN-γ and TNF-α, in contrast to interleukin (IL)-4 and IL-10, was enhanced in the lungs of mice immunized with P10 in combination with the tested adjuvants, with the best results observed in mice treated with P10 and DODAB. In conclusion, the present results demonstrate that the co-administration of the synthetic P10 peptide with several adjuvants, particularly DODAB, have significant therapeutic effects in experimental PCM. Frontiers Research Foundation 2012-05-04 /pmc/articles/PMC3343455/ /pubmed/22586420 http://dx.doi.org/10.3389/fmicb.2012.00154 Text en Copyright © Mayorga, Muñoz, Lincopan, Teixeira, Ferreira, Travassos and Taborda. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) , which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Microbiology
Mayorga, Oriana
Muñoz, Julian E.
Lincopan, Nilton
Teixeira, Aline F.
Ferreira, Luis C. S.
Travassos, Luiz R.
Taborda, Carlos P.
The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
title The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
title_full The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
title_fullStr The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
title_full_unstemmed The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
title_short The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide
title_sort role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the p10 peptide
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343455/
https://www.ncbi.nlm.nih.gov/pubmed/22586420
http://dx.doi.org/10.3389/fmicb.2012.00154
work_keys_str_mv AT mayorgaoriana theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT munozjuliane theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT lincopannilton theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT teixeiraalinef theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT ferreiraluiscs theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT travassosluizr theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT tabordacarlosp theroleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT mayorgaoriana roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT munozjuliane roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT lincopannilton roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT teixeiraalinef roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT ferreiraluiscs roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT travassosluizr roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide
AT tabordacarlosp roleofadjuvantsintherapeuticprotectionagainstparacoccidioidomycosisafterimmunizationwiththep10peptide